Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Clade Therapeutics

Main focus: Novel stem cell-derived cellular therapies

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: Undisclosed

Funding stage: Private

Location: Cambridge, MA, USA


Clade Therapeutics is focused on the development of next-generation cellular therapies, applying its induced pluripotent stem cell (iPSC)-based platform. Using its technology, it is able to generate iPSC-derived adult T, natural killer (NK) and B cells. The company is co-founded by Chad Cowan, a CRISPR Therapeutics co-founder, however, exactly how gene editing is used in the cell therapies under development has not yet been undisclosed.


HashtagClade Therapeutics

Company: Clade Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine